SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a promising earnings report, which highlighted a substantial new credit facility and several Material Transfer Agreements, notably one focused on oncology. The community is optimistic about the diversification potential of its Matrix-M adjuvant in new therapeutic areas, with discussions also circling around short interest and the strategic influence of major shareholders.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending after strong earnings and bullish guidance have validated confidence in the AI sector, yet its muted immediate price reaction is fueling community debate over market manipulation and the AI boom's future, further complicated by ongoing chip export concerns to China.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is experiencing a significant downturn following a substantial earnings and revenue miss, leading to widespread investor frustration and questions about management's credibility, while some observers cautiously eye the sharp pullback as a potential buying opportunity given the broader demand for battery energy storage systems.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending after reporting strong financial results and a bullish outlook, amplified by its strategic acquisition of SkyWater Technology and a significant defense contract award; this has ignited community discussion, with proponents highlighting its quantum computing leadership while skeptics question its valuation and long-term profitability.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius (CELH) is surging after a strong earnings report exceeded expectations and positive comments from a recent conference revealed significant shelf-space gains for its brands, particularly Alani Nu, and strong international growth potential. While bulls celebrate robust performance and anticipate continued expansion, community discussions also include concerns over the CEO's communication style and speculative theories about a potential PepsiCo buyout.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending after reporting strong revenue and customer growth in its latest quarter, with the market increasingly noting its dominance as China's intense coffee price war appears to be easing. The community is weighing rapid store expansion and perceived undervaluation against lingering concerns over profit margins and the ongoing desire for a US market relisting.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following financial results that highlight strong revenue growth and new partnerships, particularly in defense and government sectors, bolstering optimism for its dual-platform technology and commercial potential. Nevertheless, significant operating losses and its valuation continue to spark intense community debate about its long-term viability and pathway to profitability within the evolving quantum computing landscape.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending after exceeding earnings expectations and announcing a substantial new share buyback program, leading many in the community to view the stock as deeply undervalued and oversold despite broader market concerns about AI disruption to the software sector.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Despite Briumvi's robust revenue growth and recently published strong long-term efficacy data, TG Therapeutics' stock faces investor frustration due to elevated operating expenses and conservative guidance, leading to calls for management to prioritize shareholder value. The community actively debates the path forward, with discussions centered on the potential for an acquisition and the impact of significant short interest on the stagnant share price.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending following strong financial results, including profitability, coupled with the FDA approval of ORLADEYO for pediatric use and highly anticipated data for their long-acting navenibart. The community is actively discussing a potential short squeeze and whether the company's achievements will finally attract broader market recognition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten brokerages that are currently covering the company...

<ul class="summary-bullets"><li>The company now expects data from the program in the fourth quarter of 2026.&nbsp;</li><li>The program spans across 43 countries and over 500 sites and will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12.&nbsp;</li><li>The company plans to submit an application seeking approval for the therapy to the U.S. Food and Drug Administration in 2027.</li></ul>Shares of Celldex (CLDX) closed 24% higher on Wednesday after the company said that it has completed enrollment in a global late-stage program of Barzolvolimab in Chronic Spontaneous Urticaria ahead of schedule and data from it is now expected in the fourth quarter 2026.Overall, 1939 patients were enrolled in the program which includes two trials, the company said. The program spans across 43 countries and over 500 sites and will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12. &nbsp;“Completing enrollment in these large Phase 3 CSU studies 6 months ahead of guidance highlights the significant unmet need in CSU…” said CEO Anthony S. Marucci.<h2 class="st-heading-2">Trial Goal And Design</h2>The company plans to submit an application seeking approval for the therapy to the U.S. Food and Drug Administration in 2027 based on the data. The Phase 3 Program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment.Chronic spontaneous urticaria (CSU) is a skin condition characterized by itchy wheals (hives), angioedema (swelling), or both, occurring daily or almost daily for more than six weeks without an identifiable external trigger.As per data from the company’s mid-stage study of barzolvolimab in CSU, barzolvolimab has the potential to deliver symptom free complete control and dramatic improvements in quality of life and angioedema. Up to 51% of patients on the study had a complete response and were symptom free at 12 weeks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CLDX stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user expressed optimism for the company’s market capitalization rising up to $25 billion on the strength of barzolvolimab’s annual sales. The user expects the drug’s sales to out perform Dupixent, a drug &nbsp;jointly developed and manufactured by Sanofi and Regeneron Pharmaceuticals, Inc.<stembedurl>https://www.stocktwits.com/free2dream/message/645895513</stembedurl>According to data from Koyfin, the average price target on CLDX is $53.36, representing a potential upside of about 73% from current trading levels. Of the 16 analysts covering the stock, 13 rate it ‘Buy’ or higher while two rate it ‘Hold’ and one rates it a ‘Strong Sell.’<a href="https://stocktwits.com/symbol/CLDX">CLDX stock</a> has risen over 48% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/syn-tsla-stocks-rise-on-reports-of-upcoming-govt-meeting-to-discuss-robotics-policies/cZRyiIbRIGq">SYM, TSLA Stocks Rise On Reports Of Upcoming Govt. Meeting To Discuss Robotics Policies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Celldex Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent 

The company said it has enrolled patients in its late-stage program ahead of schedule. 

Equity

The company said it has enrolled patients in its late-stage program ahead of schedule. 


Celldex Therapeutics (NASDAQ:CLDX) Sees Strong Trading Volume - Still a Buy?

Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume - Here's Why...

Celldex Therapeutics (NASDAQ:CLDX) Trading 6.3% Higher - Still a Buy?

Celldex Therapeutics (NASDAQ:CLDX) Trading Up 6.3% - Still a Buy...

Readystate Asset Management LP Sells 288,480 Shares of Celldex Therapeutics, Inc. $CLDX

Readystate Asset Management LP trimmed its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 86.1% in the third quarter, according to the company in its most recent Form 13F...

Celldex Therapeutics (CLDX) Expected to Announce Earnings on Thursday

Celldex Therapeutics (NASDAQ:CLDX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Celldex Therapeutics Teases Key Barzolvolimab Phase 3 Updates, New Data at Guggenheim Summit

Celldex Therapeutics (NASDAQ:CLDX) executives used a presentation at the Guggenheim Emerging Outlook Biotech Summit 2026 to outline upcoming clinical milestones for barzolvolimab across multiple...

Celldex Therapeutics Breaks Below 200-Day Moving Average - Notable for CLDX

In trading on Thursday, shares of Celldex Therapeutics, Inc. (Symbol: CLDX) crossed below their 200 day moving average of $23.76, changing hands as low as $23.61 per share. Celldex Therapeutics, Inc...

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten brokerages that are covering the company, MarketBeat.com...

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Sees Large Growth in Short Interest

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totaling...

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

CLDX
Celldex Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CLDX News

CLDXCelldex Therapeutics Inc.